RCM
JANX icon

Raleigh Capital Management’s Janux Therapeutics JANX Stock Holding History

Raleigh Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-270
Closed -$2.9K – 1081
2023
Q4 		$2.9K Buy
+270
New +$2.33K ﹤0.01% 833

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Raleigh Capital Management's JANX Position: Q1 2024 in Review

Raleigh Capital Management sold out of Janux Therapeutics (JANX) in Q1 2024, closing a stake of 270 shares — an estimated $2.9K sold.

Raleigh Capital Management first reported a position in JANX in Q4 2023 and held it in 1 quarter. The position peaked at $2.9K in Q4 2023. 121 funds tracked by Wall St. Rank hold JANX as of Q1 2024.

  • Raleigh Capital Management reported no remaining Janux Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 270 Janux Therapeutics shares in Q1 2024, an estimated $2.9K.
  • Raleigh Capital Management first reported a position in Janux Therapeutics in Q4 2023 and held it in 1 quarter.
  • Raleigh Capital Management's Janux Therapeutics position peaked at $2.9K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.